| Family: | Krane Shares |
| Name: | KraneShares MSCI All China Health Care Index ETF |
| Inception Date: | 1-Feb-2018 |
| Termination Date: | |
| Investment Objective: | KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies. |
| Prospectus | |
| Top 10 Holdings | ||
| BEONE MEDICINES LTD-H | 6160 | 9.4995% |
| INNOVENT BIOLOGICS INC | 1801 | 8.2408% |
| WUXI BIOLOGICS CAYMAN INC | 2269 | 8.0036% |
| JIANGSU HENGRUI PHARMACEUT-A | 600276 | 7.8808% |
| AKESO INC | 9926 | 4.2976% |
| SHENZHEN MINDRAY BIO-MEDIC-A | 300760 | 4.2748% |
| SINO BIOPHARMACEUTICAL | 1177 | 4.2744% |
| CSPC PHARMACEUTICAL GROUP LT | 1093 | 4.0988% |
| HANSOH PHARMACEUTICAL GROUP | 3692 | 3.4474% |
| WUXI APPTEC CO LTD-A | 603259 | 3.0617% |
| Top 10 Holdings Weight: | 57.1% |
| Number of Holdings: | 55 |
| Shares Outstanding: | 4,750,002 |
| Total Net Assets: | 87,922,540 |
| NAV: | 18.26 |
| Net Expense Ratio: | 0.65% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Emerging Market Funds |
| Country: | China |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | International |
